About
Lilly Asian Ventures makes venture capital investments in Asia for Eli Lilly and Company, a global innovation-driven pharmaceutical company. Lilly Asian Ventures invests in promising life science companies with strong management teams and innovative technology and/or business models. Their initial focus will be primarily on opportunities in China, although they will consider investment opportunities elsewhere in east and south Asia.
Lilly Asia Ventures, founded in 2008, is dedicated to venture capital investments in the life sciences and healthcare sectors in Asia, particularly in China. Its investors include
Eli Lilly & Co., a Fortune 500 company and one of the most globalized and innovative pharmaceutical companies in the world. As a leading biomedical venture fund in China, Lilly Asia Ventures provides wise capital, industry expertise, and global resources to its portfolio companies to accelerate their growth.
Investment criteria
Pre-seed
—
Seed
Invests
Series A
Invests
Series B
Invests
Growth
Invests
- Cheque size
- $7M – $12M
- Sectors
- Healthcare & Life SciencesVenture Capital & Private Equity
- Geographies
- Canada · China · Hong Kong · Israel · Japan · South Korea · United States
- Round role
- Leads and co-leads rounds
Highlights
Highlights coming soon
Notable work and milestones will show up here.

